Clovis Oncology
Clovis Oncology's Q1 Rubraca Sales Fall 10 Percent
Sales of the PARP inhibitor were $34.2 million in the first quarter, a 10 percent decrease year over year.
In Brief This Week:Â Taiho Oncology, PamGene, Mursla, Autolus Therapeutics, Clovis Oncology
News items for the week of March 28, 2022.
Clovis Oncology, Evergreen Theragnostics Developing Actinium-225-Labeled Radionuclide
The two companies will advance radiolabeling chemistry and analytical methods for future preclinical and clinical studies of 225Ac-FAP-2286.
Clovis Oncology's Rubraca Revenues Decline 16 Percent
The company attributed the lower revenues primarily to fewer ovarian cancer patients being diagnosed and treated in the US due to the COVID-19 pandemic.
Clovis Announces Preliminary Q4 Financials; Provides Updates on Rubraca, Radionuclide Programs
Although Clovis' revenues declined last year compared to 2020, the firm is hoping for a better 2022 and anticipating important data readouts that may broaden Rubraca's market.
Nov 3, 2021
Clovis' Q3 Rubraca Sales Drop 2 Percent
Aug 4, 2021